The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...
The two-year results of TRILUMINATE trial showed the first objective benefit to use of Abbott Laboratories’ Triclip ...
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks ...
Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive license to a preclinical-stage, ...
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.
Investor's Business Daily on MSN6d
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1Novo Nordisk stock slipped 1.2% to 69.30. Novo Nordisk Is On A Licensing Spree. This is the second big weight-loss deal from Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback